Halozyme Therapeutics, Inc. (HALO) 2018年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KxANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2018ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the

2、transition period from to Commission File Number 001-32335_HALOZYME THERAPEUTICS,INC.(Exactnameofregistrantasspecifiedinitscharter)_Delaware 88-0488686(Stateorotherjurisdictionofincorporationororganization)(I.R.S.EmployerIdentificationNo.)11388 Sorrento Valley Road,San Diego,CA 92121(Addressofprinci

3、palexecutiveoffices)(ZipCode)(858)794-8889(Registrantstelephonenumber,includingareacode)Securities registered under Section 12(b)of the Act:Title of Each Class Name of Each Exchange on Which RegisteredCommon Stock,$0.001 Par Value The NASDAQ Stock Market,LLCSecurities registered under Section 12(g)o

4、f the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.x Yes NoIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes x NoIndicate by check mark whether the re

5、gistrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirementsfor the past 90 days.x

6、Yes NoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit suc